Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | YH001 + YH002 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
YH001 | YH 001|YH-001 | CTLA4 Antibody 31 | YH001 is a humanized anti-CTLA4 antibody that may block immunosuppression in tumor microenvironment and enhance antitumor immune response (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 2577-2577). | |
YH002 | YH 002|YH-002 | OX40 Antibody 14 | YH002 is a humanized agonist OX40 (CD134, TNFRSF4) antibody that activates OX40 downstream signaling, potentially leading to anti-tumor immune response (J Clin Oncol 39, no. 15_suppl, abstract e14501). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05169697 | Phase I | YH001 + YH002 | A Study to Assess YH002 in Combination With YH001 in Subjects With Advanced Solid Tumors | Recruiting | AUS | 1 |